Semaglutide news

All news on Semaglutide (also known as Wegovy and Ozempic): plants, production capacities, investments and involved companies in Europe.

5 September 2025
Novo Nordisk to Present Semaglutide and Pipeline Data at EASD Congress
Novo Nordisk to present data on semaglutide's effects on food noise, body composition, and cardiovascular benefits, plus new obesity treatments at EASD 2025.
31 August 2025
Novo Nordisk: Wegovy® Reduces Heart Attack, Stroke, Death Risk by 57% vs. Tirzepatide
Wegovy® shows 57% greater risk reduction in heart events vs. tirzepatide in obese patients with CVD. Benefits are specific to semaglutide, not general to GLP-1 or GIP/GLP-1 classes.
6 May 2013
Novo Nordisk Invests DKK 380 Million in Kalundborg Plant
The investment will create 50 jobs and convert existing facilities for semaglutide production, a new type 2 diabetes treatment. The plant will be operational by Q1 2014.

Who will be producing Semaglutide in the future?

Find out with chemXplore Analytics